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Summary.-The present studies in mice and cancer-bearing patients, treated with
C. parvum (CP) immunotherapy, were to determine the effects of CP on the produc-
tion of immune complexes (IC) and associated disease.
Using the Clq-binding assay, circulating immune complexes were detected in mice
given a single high dose of CP (466 ,ug) and repeated human-equivalent doses (70 ,ug).
All mice treated with CP developed proliferative glomerulonephritis, the severity of
which was dose-related. The histological and immunofluorescent patterns of the
nephritis were those attributed to immune-complex disease. The mice had haemat-
uria but were not in renal failure.
Fifty patients with inoperable lung cancer were studied. All received radiotherapy.
Twenty-two had no other treatment (controls) and 28 were treated with infusions of
CP. Using 2 immune-complex assays (Clq binding and monoclonal rheumatoid-
factor binding) IC were found in 10/22 control patients but these did not develop
haematuria or proteinuria. Twenty-four of the 28 patients treated with CP developed
transient haematuria and/or proteinuria with red-cell and hyaline casts, the changes
resolving over 5 days. Immune complexes were detected in 5 of these 28 patients
before CP treatment. Although 16/28 had IC at the time ofhaematuria and proteinuria,
these findings were difficult to interpret because IC may occur in response to the
tumour, the radiotherapy, or the CP. Although no patient developed renal failure, we
believe that those treated with CP should have regular assessment of their renal
function.
CORYNEBACTERIUM PARVUM (CP) is an
immunopotentiating agent (Halpern et
al., 1953; Howard et al., 1973) which in-
hibits the growth of a variety of animal
tumours (Halpern et al., 1966; Smith &
Scott, 1972; Sadler & Castro, 1976). It has
been used to treat patients with malignant
disease (Israel, 1975; Takita & Moayeri,
1976; Sarna et al., 1977). In 1978 Dosik
et al. reported 4 cancer patients who de-
veloped renal failure while receiving re-
peated infusions of CP. Renal function
recovered after the CP was stopped. This
reversibility of the renal failure, together
with the histological features that they
described, suggested that these patients
had immune-complex nephritis due to CP.
The present studies were to determine, in
mice and in patients with cancer receiving
CP immunotherapy, the effects of re-
peated treatments of CP on production of
immune complexes (IC) and associated
disease. The cancer-bearing patients were
part of a controlled clinical trial designed
to evaluate the anti-tumour effects of CP.
MATERIALS, PATIENTS AND METHODS
C. parvum.-A formalin-killed suspension
of C. parvum (Wellcome, strain CN 6134,
7 mg dry wt/ml) was used.
Mice.-Adult female age-matched C57BL/
10 ScSn mice (Olac Southern Ltd) were
divided into 4 groups which were treated
thus: (i) 16 animals received a single low dose
of 70 ug CP (a "human equivalent" dose
calculated from our clinical dose of 10 mg/M2
relating the surface area of a 20g mouse to a
70kg human); (ii) 16 animals received a singleIMMUNE-COMPLEX DISEASE AFTER C. PARVUAI3
hiigh dose of 466 jug of CP (our usual mouse
dose): (iii) 16 animals received weekly injec-
tions of 70 jtg of CP; (iv) 16 animals had no
treatment and acted as controls.
All treatments were given i.v. Four animals
from each group were killed with ether at
1, 6, 9 and 12 weeks from the start of the
study.
Patients.-Fifty patients with inoperable
bronchial carcinoma, after giving informed
consent, entered a prospective randomized
clinical study. There were 10 females and 40
males. The mean age wa.s 57 7 years (range
29-80). All received radiotherapy. Twenty-
twNo had no other treatment and acted as
"controls"; 28 were additionally treated with
CP at a dose of 10 mg/M2 surface area giveni
by i.v. infusion in 100 ml of5°/ dextrose over
1 h. Treatments were repeated monthly to a
planned total of4 treatments for each patient.
Samples ofblood and urine were taken imme-
diately before and 2 days after each CP
infusion. Control patients were seen every 2
months.
CP antibody. Antibodies to CP were
measured by passive agglutination. Doubling
dilutions ofserum were made with phosphate-
buffered saline to a total volume of 50 ,u in
each well of microtitre plate. 25 jul of a
0 7 mg/ml CP suspension was added to each
well. The mixtures were incubated for 2 h at
37°C and then at 4°C for 48 h. Agglutination
was observed and the antibody titres ex-
pressed as pow-ers of 2.
Urine analysis.-Urine was examined for
blood and protein using Multistix (Ames).
Specimens were centrifuged and the deposits
examined bv light microscopy.
ITt1wlmmune-conmplex assay,s
Clq-binding (ClqB). This assay was per-
formed as previously described (Pussell et al.,
1978). Purified radiolabelled Clq was incu-
bated with test sera in the presence of ethyl-
enediaminetetra-acetate (EDTA). Free and
bound Clq were then separated by precipita-
tion with polyethylene glycol (mol. wt 6000).
The amount ofradioactivity in the precipitate
was taken to represent the amount ofimmune
complexes. Results were expressed as the
percentage of total protein-bound radio-
activity. In human sera, levels >2-70; were
considered abnormal (Pussell et al., 1978).
The same assay using Clq wNas used to test
mouse sera. Normal untreated mice had a
mean level of 16 6 + 10-.0%. Levels exceeding
30% were considered abnormal.
Monoclonal rheumatoid factor (niRF).
Purified monoclonal IgM rheumatoid factor
was radiolabelled and used in a similar assay
to the ClqB assay (Barratt & Naish, 1979).
Levels of binding > 20% were considered
abnormal.
Rheumatoid factor. A latex slide test
(Rheuma-Welleotest, Wellcome) was used to
detect rheumatoid factor in human serum.
Positive samples were quantitatively titrated.
Immunofluorescence.-Mouse immunoglo-
bulins were detected by direct immuno-
fluorescence (Johnson et al., 1978) using
fluorescent rabbit anti-mouse immunoglobu-
lin (Northeast Biomed/Med. Labs. Ltd.).
Mouse complement was detected by in-
direct immunofluorescence (Johnson et al.,
1978). The first layer of unlabelled serum
raised in sheep to mouse C3 (previously shown
to be monospecific), was used at a dilution of
1 in 20. The second layer was fluorescent
rabbit anti-sheep immunoglobulin (Well-
come) at a dilution of 1 in 20.
Antigenic C3.-C3 was measured by radial
immuno-diffusion against monospecific anti-
sera. Results were expressed as percentage
pooled normal human serum (normal range
60-1400/).
Statistical methods. Non-parametric data
were ranked using theWilcoxon test for paired
data, the Mann-Whitney U test for unpaired
data, and Spearman's coefficient for correla-
tions. Parametric analysis (t test) was applied
via the central-limit theorem to appropriate
data.
RESULTS
Mice
CP antibody titre. Untreated mice had
a low natural level of CP antibody. At
6 weeks a single low dose of CP increased
the titre to 12 (power of 2) and a high dose
to 14. Repeated low doses stimulated a
more pronounced rise, to a titre of 25.
Urine analysis and serum urea concen-
tration. Untreated mice had normal
urine analysis. Those receiving single
doses had trace (Multistix) haematuria
and those receiving repeated doses had
moderate haematuria. Proteinuria was not
detected. The median urea concentration
was similar for each group and there was
no statistical difference between groups.
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Circulating immune complexes.-The re-
sults of the Clq-binding assay are shown
in Fig. 1. There were no differences be-
tween those treated with a single low dose
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FiG. 1. Effect of CP on Clq binding in mice.
Each point represents the median of 4
samples, with a bar to indicate some of the
range.
and control animals. Mice given a single
high dose had significantly increased
binding at 1 week (P < 0.05) but this re-
turned to normal thereafter. Those re-
ceiving repeated low doses had a highly
significant (P < 0-001) and prolonged in-
crease in binding at all intervals.
Light microscopy. Kidneys from con-
trol mice were normal. Kidneys from all
animals receiving CP were abnormal. By
1 week, animals receiving a single low
dose showed glomerular changes of mild
segmental proliferation, superimposed on
a background ofdiffuse mesangial promin-
ence (Fig. 2). Those receiving a single high
dose had moderate mesangial prolifera-
tion, which was more diffuse but with
some segmental accentuation. Occasional
crescents were present. Tubules and inter-
stitium were unaffected. At 6 and 9 weeks
the changes were similar, but there was
scarring and less proliferation. Kidneys
from mice receiving repeated low doses
examined at 6 weeks showed marked
diffuse mesangial proliferation in their
glomeruli, with frequent crescents (Fig. 3).
There was some necrosis but few poly-
morphs and the capillary loops did not
appear thickened. The tubules and inter-
stitium were normal. Three weeks later
there appeared to be some recovery, as
there were fewer crescents, mesangial
proliferation was slightly reduced and the
mesangial matrix was increased.
Immnunofiuorescence. Kidneys from
control mice did not stain for complement.
Some control mice had small amounts of
granular mesangial staining for immuno-
globulin. By 1 week those animals that
received a single dose (low or high)
showed moderate granular mesangial
staining for both immunoglobulin and
complement (Fig. 4). At 9 weeks immuno-
globulin staining had returned to the
levels seen in control animals, but mild
complement staining persisted.
By 6 weeks mice receiving repeated
low doses showed mild granular mesangial
staining for immunoglobulin, and con-
siderable granular mesangial staining for
complement. At 9 weeks there was virtu-
ally no staining for immunoglobulin but
considerable complement staining per-
sisted. Granular deposits were seen in the
capillary loops as well as in the mesan-
gium.
Cancer patients
Twenty-eight patients treated with CP
received a total of 63 infusions. Eight
completed the planned course of infusions
and 3 others continue in the programme.
Seventeen failed to complete the pro-
gramme; 5 withdrew with disease pro-
gression to a pre-terminal phase and 12
considered the side-effects of the treat-
ment unacceptable (fever, malaise and
rigors) and refused further infusions.
Twenty-two control patients were seen on
a total of 43 occasions.
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FIG. 2. Glomerulus from mouse one week after si.igle dv. (1oSe Of 70 , CP, sho-wing mild segmeintal
proliferative glomerilonep)hritis. I'AS, x 550.
titre (power of 2) in (P-treated patients
rose progressively with each infusion,
reaching a median level of 13 (range 10-16)
after 4 infusions. Control patients had a
median titre of 7 (range 6- 11).
Urine analysis and serumt urea and
creatinine concentrations.-Twenty-four of
the CP-treated patients had haematuria
and/or proteinuria after CP infusion. In
some patients haematuria occurred only
once, but in 5 it was found after every
infusion. Haematuria and proteinuria de-
veloped 1 day after treatment, were
great,est on the 2nd or 3rd day, and had
resolved by the 4th or 5th day. Haemat-
uria was confirmed by the presence of red
blood cells. Red-cell and hyaline casts
were seen. None of the control patients
had haematuria or proteinuria. All
patients had normal urea and creatinine
concentrations and CP treatment did not
affect these.
Immnune complex. Immune-complex
measurements showed good correlation
between the ClqB assay and the mRFA
(r=0-89, n=150). ICs were detected
before treatment in 5 CP patients. No
significant acute change in Clq binding
was detected when pre- and post-CP
treatment values were compared, and
there was no difference between patients
with, and those without, haematuria and
proteinuria. However, over the 4 months,
there was a gradual rise in Clq binding, so
that IC were detected in 17 patients after
CP. In 16 these were associated with
haematuria and proteinuria. IC was de-
tected in 6 of the control patients before
treatment and in 10 4 months after start-
ing radiotherapy.
Rheumatoid factor. Rheumatoid factor
was detected in the serum of 5 CP
patients and 5 controls. These patients,
excepting 1 CP and I control, had IC.
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FIG. 3. Glomerulus from mouse after 6 i.v. doses of 70 ,tg CP, showing severe diffuse proliferative
glomerulo-nephritis. PAS, x 550.
FIG. 4.-Glomerulus from mouse one week after single i.v. dose of 70 Ftg CP, showing granular
mesangial staining for complement. Indirect immunofluorescence, x 350.
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None had cliniical evidence of rheumatoid
arthritis.
Antigenic C3. (C3 levels were high in
all patients (mean 162 + 45%). Levels
were uinaltered by CP.
DISCUSSION
Wle have shown that proliferative
glomerulonephritis occurs in mice after
CP injection, and the severity is dose-
related. WNe believe this is an immune-
complex disease, firstly because the im-
munofluorescent and histological patterns
were similar to those described by Wilson
& Dixon (1976) in their experimental
model of acute serum sickness, and by
Cochrane & Koffler (1973) in human renal
disease attribuited to immune complexes.
Secondly, circulating immune complexes
were detected by the Clq-binding assay in
mice given a single high dose and re-
peated low doses of CP. Even though
normal mouse serum bound considerably
more Clq than normal human serum,
there was significantly increased binding
in mice receiving repeated CP.
An interesting observation was the
failure to detect circulating IC in mice
given a low dose of CP, despite histo-
logical and immunofluorescent evidence of
an IC type of glomerulonephritis, albeit
mild. Several possible explanations exist.
It is conceivable that our test for circu-
lating IC was insensitive, as shown by the
high background binding in mouse serum.
Intermittent generation of circulating IC
may cause sampling problems; thus a
transient burst of IC in the circulation
might not be detected. It is also possible
that in this group antigen does not circu-
late but is deposited in the kidney where
local tissue ICs are formed. In this respect
higher doses of CP might lead to overflow
ofICs into the circulation, thus permitting
their detection.
Our finding of circulating 1C in 10/22
control patients with lung cancer supports
that of Gropp et al. (1979) and compares
with our unpublished observation that ICs
were detected in only 2/30 age-comparable
patients with stable chronic renal failure.
These control patients with lung cancer
did not develop haematuria or protein-
uria. Twenty-four of 28 patients treated
with CP had haematturia and/or protein-
uria associated with one or more CP
infusion, but no significant acute change
in IC was detected. However, there was a
gradual increase in circulating IC over 4
months. This gradual increase may be
interpreted as tumour-associated com-
plexes developing as a result of tumour
progression. In addition, radiotherapy
leads to increased amounts of IC (GQropp
et al., 1979). It is also possible that CP
causes circulating IC. If haematuria and
proteinuria in these patients were caused
by IC formed in response to CP, we pro-
pose that there must exist 2 or more popu-
lations of complexes: one associated with
the tumour, which does not cause kidnev
damage, and another induced by CP,
which does. In this connection, patients
with systemic lupus erythematosus (a
putative complex disease) have been
shown to have complexes of different
sizes, those with smaller IgG-containing
complexes being more likely to develop
nephritis than those with larger complexes
(Levinsky & Soothill, 1979).
We have not attempted to identify the
antigen responsible for the IC disease in-
duced in mice by CP. It is possible that
the antigen is CP itself, or that the
powerful adjuvant action of CP (Sljivic &
Watson, 1977) may stimulate a response
to another unknown antigen.
In conclusion, mice treated with CP
developed proliferative glomerulonephritis
due to immune-complex deposition. Thev
had haematuria but not renal failure.
Patients with lung cancer treated with CP
often developed haematuria and protein-
uria. Immune complexes may occur in
these patients in response to the tumour,
to radiotherapy or to CP. Although none
of our patients developed renal failure, we
agree with Dosik et al. (1978) that those
treated with CP should have regular
assessment of their renal function.
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